| Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. | |
| | |
MedLine Citation:
|
PMID: 17593631 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: p53 is a tumour suppressor gene, which is mutated in more than half of all tumours. Most chemotherapeutic drugs cause DNA damage, which is sensed by p53; the cell can then try to repair the damage or induce cell suicide. If the p53 machinery is defective, effective chemotherapy is made more difficult. MATERIALS AND METHODS: Wild-type p53 was transfected into lung cancer cell lines with different p53 status. The transfected cells were tested for changes in sensitivity to a range of chemotherapeutic agents. RESULTS: We observed only modest changes in the sensitivity to the chemotherapeutic agents adriamycin, taxol and carboplatin in the transfected cells lines. p53 protein was detected in a transfected clone of the cell line H1299, whose parent cells are p53 null. However, the protein did not accumulate after DNA damage, suggesting that this cell line utilises alternative pathways for responding to stress, and no longer has a functional p53 pathway. CONCLUSION: The results suggest that introduction of wild-type p53 alone is not sufficient to substantially alter the sensitivity of a cell line to a given chemotherapeutic agent. |
| | |
Authors:
|
Laura Breen; Mary Heenan; Verena Amberger-Murphy; Martin Clynes |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Anticancer research Volume: 27 ISSN: 0250-7005 ISO Abbreviation: Anticancer Res. Publication Date: 2007 May-Jun |
Date Detail:
|
Created Date: 2007-06-27 Completed Date: 2007-07-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 1361-4 Citation Subset: IM |
Affiliation:
|
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. laura.breen@dcu.ie |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carboplatin
/
pharmacology Cell Line, Tumor Doxorubicin / pharmacology Drug Resistance, Multiple Drug Resistance, Neoplasm Humans Inhibitory Concentration 50 Lung Neoplasms / drug therapy*, genetics, metabolism Paclitaxel / pharmacology Plasmids / genetics Transfection Tumor Suppressor Protein p53 / biosynthesis, genetics, metabolism, physiology* |
| Chemical | |
Reg. No./Substance:
|
0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 23214-92-8/Doxorubicin; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: DNA microarray-based transcriptomic profiling of an isogenic cell culture model of breast tumour cel...
Next Document: Practical guidelines for diagnostic use of in vitro chemosensitivity tests.